Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 47

Related Articles by Review for PubMed (Select 21415101)

1.
2.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
4.

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N.

Diabetes Obes Metab. 2008 Dec;10(12):1221-38. doi: 10.1111/j.1463-1326.2008.00892.x. Epub 2008 May 26. Review.

PMID:
18505403
5.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
6.

[Heart failure with thiazolidinedione treatment: what do we know today?].

Erdmann E.

Dtsch Med Wochenschr. 2009 Jan;134(4):154-8. doi: 10.1055/s-0028-1123973. Epub 2009 Jan 15. Review. German.

PMID:
19148858
7.

Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.

Hernandez AV, Usmani A, Rajamanickam A, Moheet A.

Am J Cardiovasc Drugs. 2011;11(2):115-28. doi: 10.2165/11587580-000000000-00000. Review.

PMID:
21294599
8.

[Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].

De Flines J, Scheen AJ.

Rev Med Suisse. 2007 Aug 29;3(122):1876, 1878-83. Review. French.

PMID:
17896661
9.

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C.

BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169. Review.

10.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

11.
12.

Rosiglitazone and cardiovascular risk.

Kaul S, Diamond GA.

Curr Atheroscler Rep. 2008 Oct;10(5):398-404. Review.

PMID:
18706281
13.

Safety and efficacy of rosiglitazone in the elderly diabetic patient.

Viljoen A, Sinclair A.

Vasc Health Risk Manag. 2009;5(1):389-95. Review.

14.

[Therapy with glitazones--a risk for cardiovascular disease?].

Rottlaender D, Michels G, Erdmann E, Hoppe UC.

Dtsch Med Wochenschr. 2007 Dec;132(49):2629-32. Review. German.

PMID:
18050028
15.

The cardiovascular safety of rosiglitazone.

Ajjan RA, Grant PJ.

Expert Opin Drug Saf. 2008 Jul;7(4):367-76. doi: 10.1517/14740338.7.4.367 . Review.

PMID:
18613801
16.

Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

Mudaliar S, Chang AR, Henry RR.

Endocr Pract. 2003 Sep-Oct;9(5):406-16. Review.

PMID:
14583425
17.

Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.

Derosa G.

Drugs. 2010 Oct 22;70(15):1945-61. doi: 10.2165/11538100-000000000-00000. Review.

PMID:
20883052
18.

Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.

Wang AT, McCoy CP, Murad MH, Montori VM.

BMJ. 2010 Mar 18;340:c1344. doi: 10.1136/bmj.c1344. Review.

19.

Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.

Bourg CA, Phillips BB.

Ann Pharmacother. 2012 Feb;46(2):282-9. doi: 10.1345/aph.1Q400. Epub 2012 Jan 31. Review.

PMID:
22298606
20.

Do thiazolidinediones cause heart failure? A critical review.

Tang WH.

Cleve Clin J Med. 2006 Apr;73(4):390-7. Review. Erratum in: Cleve Clin J Med. 2006 Jun;73(6):588.

PMID:
16610400
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk